University of Milan, Milan, Italy.
Thoracic Surgery and Lung Transplantation Unit, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Transpl Int. 2023 Feb 8;36:10690. doi: 10.3389/ti.2023.10690. eCollection 2023.
Donation after cardiac death (DCD) donors are still subject of studies. In this prospective cohort trial, we compared outcomes after lung transplantation (LT) of subjects receiving lungs from DCD donors with those of subjects receiving lungs from donation after brain death (DBD) donors (ClinicalTrial.gov: NCT02061462). Lungs from DCD donors were preserved through normothermic ventilation, as per our protocol. We enrolled candidates for bilateral LT ≥14 years. Candidates for multi-organ or re-LT, donors aged ≥65 years, DCD category I or IV donors were excluded. We recorded clinical data on donors and recipients. Primary endpoint was 30-day mortality. Secondary endpoints were: duration of mechanical ventilation (MV), intensive care unit (ICU) length of stay, severe primary graft dysfunction (PGD3) and chronic lung allograft dysfunction (CLAD). 121 patients (110 DBD Group, 11 DCD Group) were enrolled. 30-day mortality and CLAD prevalence were nil in the DCD Group. DCD Group patients required longer MV (DCD Group: 2 days, DBD Group: 1 day, = 0.011). ICU length of stay and PGD3 rate were higher in DCD Group but did not significantly differ. LT with DCD grafts procured with our protocols appears safe, despite prolonged ischemia times.
心脏死亡后捐献(DCD)供体仍在研究中。在这项前瞻性队列研究中,我们比较了接受 DCD 供体肺的肺移植(LT)患者与接受脑死亡后捐献(DBD)供体肺的患者的结局(ClinicalTrials.gov:NCT02061462)。按照我们的方案,DCD 供体的肺通过常温通气来保存。我们招募了双侧 LT 候选者≥14 岁。多器官或再次 LT 候选者、年龄≥65 岁的供体、DCD 类别 I 或 IV 供体被排除在外。我们记录了供体和受体的临床数据。主要终点是 30 天死亡率。次要终点是:机械通气(MV)持续时间、重症监护病房(ICU)住院时间、严重原发性移植物功能障碍(PGD3)和慢性肺移植功能障碍(CLAD)。共纳入 121 例患者(110 例 DBD 组,11 例 DCD 组)。DCD 组 30 天死亡率和 CLAD 发生率均为零。DCD 组患者需要更长的 MV(DCD 组:2 天,DBD 组:1 天,=0.011)。DCD 组 ICU 住院时间和 PGD3 发生率较高,但差异无统计学意义。尽管缺血时间延长,但使用我们的方案获取 DCD 移植物的 LT 似乎是安全的。